Development of a robust, physiologically relevant neuronal tau aggregation assay for tau-related drug discovery
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.110853 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Jessica W Wu und 17 weiteren Autor:innen. Beteiligte Einrichtung: AbbVie, Neuroscience Discovery Research, Cambridge Research Center, Cambridge, Massachusetts, USA; Former AbbVie Employees, Boston, Massachusetts, US…. Hauptthemen laut MEDLINE: tau Proteins, Neurons, Protein Aggregation, Pathological, Drug Discovery. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Massachusetts General Hospital, Mayo Clinic, AbbVie.
Abstract (Originalsprache)
Therapeutic interventions to block extracellular tau seeding to prevent endogenous tau aggregation and progression of Alzheimer's disease pathology are currently being investigated in clinical trials. However, the translation of promising preclinical findings to benefit clinical outcomes remains problematic due to the lack of pathophysiological models that recapitulate key features of sporadic Alzheimer's disease-related tauopathies. We developed a primary neuronal tau (hTau) seeding and propagation model. Neurons expressing wild-type human tau protein at a physiological level, seeded with a sub-nanomolar tau derived from Alzheimer's disease brain tissues, rapidly and robustly form tau aggregates and develop impaired mitochondrial function. Resulting aggregates are quantitatively measured using automated high-content algorithms. The considerable pathophysiological relevance, coupled with a highly sensitive dynamic range, makes this assay a valuable model system for studying tau pathobiology and an efficient screening tool for modulators of tau aggregation. Using this model, we demonstrate that by targeting a phosphorylation-specific epitope of tau, an antibody effectively stops tau aggregation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AbbVie, Neuroscience Discovery Research, Cambridge Research Center, Cambridge, Massachusetts, USA; Former AbbVie Employees, Boston, Massachusetts, USA. Electronic address: jinhua07@gmail.com.
- AbbVie, Neuroscience Discovery Research, Cambridge Research Center, Cambridge, Massachusetts, USA; Former AbbVie Employees, Boston, Massachusetts, USA.
- AbbVie, Neuroscience Discovery Research, Cambridge Research Center, Cambridge, Massachusetts, USA.
- AbbVie, Neuroscience Discovery Research, Cambridge Research Center, Cambridge, Massachusetts, USA. Electronic address: xavier.langlois@abbvie.com.
Förderung
- Massachusetts General Hospital
- Mayo Clinic
- AbbVie
Zitieren
APA
Wu, J. W., Titterton, K., Sebastian, R., Romanul, N., Yanamandra, K., Mastis, B., Chang, R., Khasnavis, S., Kwon, T., Chai, Y., Manos, J. D., Preiss, C. N., Hu, M., Welker, A. M., Liao, F., Dellovade, T., Karran, E., & Langlois, X. (2025). Development of a robust, physiologically relevant neuronal tau aggregation assay for tau-related drug discovery. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110853
Vancouver
Wu JW, Titterton K, Sebastian R, Romanul N, Yanamandra K, Mastis B, et al. Development of a robust, physiologically relevant neuronal tau aggregation assay for tau-related drug discovery. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110853
BibTeX
@article{Wu2025,
author = {Wu, Jessica W and Titterton, Katherine and Sebastian, Rebecca and Romanul, Nandini and Yanamandra, Kiran and Mastis, Bryan and Chang, Rui and Khasnavis, Saurabh and Kwon, Taekyung and Chai, Yating and Manos, Justine D and Preiss, Christina N and Hu, Miwei and Welker, Alessandra M and Liao, Fan and Dellovade, Tammy and Karran, Eric and Langlois, Xavier},
title = {Development of a robust, physiologically relevant neuronal tau aggregation assay for tau-related drug discovery},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.110853}
}
EUVIMED